Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Released by Interventional Approaches for Advanced Solid Tumors

NCT04952272 is registered in ClinicalTrials.gov with Second Affiliated Hospital of Guangzhou Medical University as lead sponsor.

NCT NCT04952272
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04952272 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Intratumor CpG-ODN Injection Boosters Immune Killing Against in Situ Tumor Antigen Released by Interventional Approaches for Advanced Solid Tumors
Lead sponsor
Second Affiliated Hospital of Guangzhou Medical University
Phase
Phase 1
Overall status
Recruiting
Start date
March 1, 2021
Completion date
June 30, 2036
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma, lung cancer, solid tumor